Verastem, Inc. (VSTM) · Oct 14, 2026 · Exec change

Verastem CEO change puts commercial veteran at KRAS pipeline helm

CEO transition — Bailey becomes CEO January 1, 2027

Verastem’s CEO transition names Michael Bailey to lead its launched ovarian-cancer drug and advance the VS-7375 KRAS G12D pipeline.

Verastem is moving from a newly commercial-stage company into a two-track execution phase: scaling AVMAPKI FAKZYNJA CO-PACK while pushing VS-7375 through three registration-directed Phase 2 programs in pancreatic, lung, and colorectal cancers. This is an orderly handoff, not a strategy reset. Michael Bailey takes over on January 1, 2027, while retiring CEO Daniel Paterson remains on the board and becomes an advisor. 〔0〕 That continuity matters because the business is at an execution-heavy inflection point rather than searching for a new direction. The appointment strengthens the commercial side of the story, but does not remove the clinical risk. Bailey brings a long record in oncology commercialization and led AVEO through the approval and launch of FOTIVDA, while Verastem’s main pipeline value still depends on preliminary VS-7375 data becoming durable, registrational evidence. The timing is the main signal. The filing arrives as Verastem is preparing to present updated VS-7375 data and move toward a Phase 3 pancreatic-cancer study; naming a commercially experienced successor suggests the board is prioritizing launch execution without abandoning the pipeline’s acceleration. 〔1〕 Bottom line: This is a continuity-positive management change rather than a new catalyst for the underlying science. It modestly improves confidence in commercial execution, but the company’s central value driver remains whether VS-7375’s clinical data hold up as development advances.

What to watch next

VS-7375 updated data and Phase 3 preparation

Original filing on SEC EDGAR

More Verastem, Inc. news

Verastem CEO change puts commercial veteran at KRAS pipeline helm | VSTM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.